Govermate logoGovermate
Back to opportunities
DocumentClosednews

Review shows effectiveness of Lenacapavir in reducing new HIV infections

South African Medical Research CouncilRef: COM/CDSR/DOI/10.1002/14651858.CD016347/FULL

Official source

Source domain: samrc.ac.za

Collected on 25 June 2026

Always confirm details on the official source before acting.

Our copy (archived 9 July 2026)Official source

What this means

The document reports on a Cochrane review funded by the South African National Department of Health, evaluating the effectiveness of Lenacapavir as a long-acting HIV pre-exposure prophylaxis (PrEP). It finds that Lenacapavir significantly reduces new HIV infections compared to oral PrEP, with fewer serious adverse effects and manageable injection site reactions. The review emphasizes the need for further research on implementation, costs, and risks in various populations.

Facts

Reference

COM/CDSR/DOI/10.1002/14651858.CD016347/FULL

Key Takeaways

  • review funded by South African NDoH
  • evaluates Lenacapavir for HIV PrEP
  • contains two large randomized trials
  • 8,660 participants worldwide
  • Lenacapavir reduces HIV infections
  • compared to oral PrEP
  • fewer serious side effects
  • may cause injection site reactions
  • study period: 2024-2028
  • full review at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016347/full